Methylprednisolone pulse therapy in acute severe asthma. A randomized, double-blind study

Area of Science:

• Pulmonology
• Immunology
• Pharmacology

Background:

• Long-term oral steroid use in asthma carries significant side effects.
• Methylprednisolone pulse therapy (MPPT) shows promise for immune-inflammatory diseases with fewer side effects.
• Reducing oral steroid dependency in severe asthma is a clinical goal.

Purpose of the Study:

• To compare the efficacy of MPPT versus a short course of oral prednisolone in treating acute severe asthma.
• To evaluate the long-term impact on lung function and steroid requirements.

Main Methods:

• Double-blind, double-dummy study design.
• Comparison of intravenous methylprednisolone (1g) with oral prednisolone.
• Inclusion of 18 patients with acute severe asthma.
• 12-week follow-up assessing FEV1 and supplementary steroid use.

Main Results:

• Both MPPT and oral prednisolone effectively relieved acute asthma attacks.
• No significant difference in the speed of symptom resolution was observed.
• MPPT group required earlier and higher doses of supplementary prednisolone.
• FEV1 levels were similar between groups after 12 weeks.
• MPPT demonstrated a shorter duration of protection against subsequent asthma attacks.

Conclusions:

• Intravenous methylprednisolone is not superior to oral prednisolone for acute severe asthma symptom relief.
• MPPT may offer a shorter duration of protection against future asthma exacerbations.
• Further research is needed to optimize steroid use in severe asthma management.